In Vitro Activitiy of Rezafungin in Comparison with Anidulafungin and Caspofungin against Invasive Fungal Isolates (2017 to 2022) in China

Simin Yang, Fangru Wan, Min Zhang, Hui‐Ping Lin, Liang Hu, Ziyi Zhou, Dongjiang Wang, Aiping Zhou, Lijun Ni, Jian Guo, Wenjuan WuJournal of Fungi 2024 · DOI

TL;DR

This study evaluates the in vitro effectiveness of rezafungin, a novel echinocandin antifungal, against common invasive fungal pathogens in China. Rezafungin demonstrated comparable activity to established echinocandins like anidulafungin and caspofungin against Candida and Aspergillus species, suggesting its potential for clinical use, particularly in regions facing rising antifungal resistance.

What Problem Does This Paper Address?

Invasive fungal infections (IFIs), primarily caused by Candida and Aspergillus species, pose a significant threat, especially to immunocompromised individuals, leading to high morbidity and mortality. The increasing prevalence of antifungal resistance, particularly to azoles, necessitates the development and evaluation of new antifungal agents. Echinocandins, which target fungal cell wall synthesis, are a crucial class of antifungals. While anidulafungin and caspofungin are established, rezafungin is a newer echinocandin with potential advantages like once-weekly dosing. However, data on rezafungin's efficacy against clinical isolates in specific geographic regions, like China, where antifungal resistance patterns might differ, is limited. This paper aims to fill this gap by comparing rezafungin's in vitro activity with existing echinocandins against a large collection of clinical fungal isolates from China.

Methods

The researchers employed standard microbiological techniques to assess antifungal susceptibility. The core method was broth microdilution (BMD), a widely accepted technique for determining minimum inhibitory concentrations (MICs) and minimum effective concentrations (MECs). This involved exposing fungal isolates to serial dilutions of the antifungal drugs in liquid culture and observing growth inhibition. For echinocandins, both MICs (for Candida) and MECs (for Aspergillus) were determined. Additionally, to investigate resistance mechanisms in C. tropicalis, the researchers performed FKS gene sequencing on isolates exhibiting high resistance to echinocandins. This targeted approach aimed to identify specific mutations in the FKS genes, which are known targets for echinocandin resistance.

Datasets

The study utilized a substantial collection of clinical fungal isolates sourced from the Eastern China Invasive Fungi Infection Group (ECIFIG). This dataset comprised:

  • 1000 clinical Candida isolates:
    • 400 Candida albicans
    • 200 Candida glabrata
    • 200 Candida parapsilosis
    • 150 Candida tropicalis
    • 50 Candida krusei
  • 150 clinical Aspergillus isolates:
    • 100 Aspergillus fumigatus
    • 50 Aspergillus flavus

These isolates were collected between January 2017 and December 2022. The study also used quality control (QC) strains (C. parapsilosis ATCC 22019, C. krusei ATCC 6258, and A. fumigatus ATCC MYA-3626) to ensure the reliability of the experimental procedures. No new benchmark datasets were introduced; the study focused on evaluating existing antifungals against a contemporary clinical isolate collection.

Key Insights and Ideas

  • Rezafungin holds its own: The most significant takeaway is that rezafungin performs comparably to established echinocandins (anidulafungin and caspofungin) against a broad spectrum of common Candida and Aspergillus species. This is crucial for a novel drug entering the market.
  • C. tropicalis is a resistance hotspot: This species stands out with higher resistance rates to echinocandins compared to other Candida species. This highlights the need for careful monitoring and potentially tailored treatment strategies for infections caused by C. tropicalis.
  • FKS mutations are key to resistance: The study directly linked echinocandin resistance in C. tropicalis to specific mutations in the FKS1 gene, particularly the S654P alteration. This provides a molecular basis for observed resistance and could inform future diagnostic approaches.
  • Echinocandins maintain efficacy against azole-resistant strains: The study observed that echinocandins, including rezafungin, retained their potent activity even against C. albicans isolates that were resistant to fluconazole. This underscores their value as alternative or salvage therapies.
  • Geographic relevance: By focusing on isolates from China, the study provides valuable data for this specific region, where antifungal resistance patterns might differ from those reported in other parts of the world.

Key Results

  • Comparable activity: Rezafungin demonstrated similar in vitro activity to anidulafungin and caspofungin against most Candida and Aspergillus species tested.
  • C. glabrata susceptibility: Rezafungin showed higher susceptibility rates against C. glabrata compared to anidulafungin and caspofungin.
  • C. tropicalis resistance: Approximately 8.67% of C. tropicalis isolates exhibited resistance to the tested echinocandins, a higher rate than other Candida species.
  • FKS1 mutations: All 13 echinocandin-resistant C. tropicalis isolates sequenced harbored mutations in the FKS1 gene, predominantly the S654P alteration.
  • Aspergillus activity: Rezafungin's MEC values against A. fumigatus and A. flavus were comparable to caspofungin but slightly higher than anidulafungin.

Limitations and Future Work

  • Limited drug comparison: The study did not include micafungin, another approved echinocandin, which is a limitation for a comprehensive comparison.
  • In vitro focus: The findings are based on in vitro susceptibility testing, and clinical outcomes may vary. Further in vivo studies and clinical trials are needed to confirm rezafungin's efficacy and safety in patients.
  • Strain storage: The tested strains were stored for 1-5 years, which the authors acknowledge might have influenced the observed resistance evolution.
  • Interlaboratory variability: The authors note that interlaboratory variability in MIC testing can occur due to various factors, though they followed CLSI guidelines.
  • Future directions: The authors suggest the need for more clinical trials to gather in vivo data for rezafungin's use. They also emphasize the importance of considering the complex interactions between fungi, drugs, and the host for personalized antifungal therapy. The findings on C. tropicalis resistance also point towards the need for enhanced environmental surveillance and disinfection protocols in healthcare settings.

Summary updated

Abstract

The efficacy of different echinocandins is assessed by evaluating the in vitro activity of a novel antifungal, rezafungin, against invasive fungal isolates in comparison with anidulafungin and caspofungin. Using the broth microdilution (BMD) method, the susceptibility of 1000 clinical <i>Candida</i> isolates (including 400 <i>C. albicans</i>, 200 <i>C. glabrata</i>, 200 <i>C. parapsilosis</i>, 150 <i>C. tropicalis</i> and 50 <i>C. krusei</i>) and 150 <i>Aspergillus</i> isolates (100 <i>A. fumigatus</i> and 50 <i>A. flavus</i>) from the Eastern China Invasive Fungi Infection Group (ECIFIG) was tested for the antifungals including anidulafungin, rezafungin, caspofungin and fluconazole. The echinocandins showed strong activity against <i>C. albicans</i> that was maintained against fluconazole-resistant isolates. The GM MIC (geometric mean minimum inhibitory concentration) value of rezafungin was found to be comparable to that of anidulafungin or caspofungin against the five tested common <i>Candida</i> species. <i>C. tropicalis</i> exhibited higher resistance rates (about 8.67-40.67% in different antifungals) than the other four <i>Candida</i> species. Through the sequencing of <i>FKS</i> genes, we searched for mutations in echinocandin-resistant <i>C. tropicalis</i> isolates and found that all displayed alterations in <i>FKS1</i> S654P. The determined MEC (minimal effective concentration) values against <i>A. fumigatus</i> and <i>A. flavus</i> for rezafungin (0.116 μg/mL, 0.110 μg/mL) are comparable to those of caspofungin (0.122 μg/mL, 0.142 μg/mL) but higher than for anidulafungin (0.064 μg/mL, 0.059 μg/mL). Thus, the in vitro activity of rezafungin appears comparable to anidulafungin and caspofungin against most common <i>Candida</i> and <i>Aspergillus</i> species. Rezafungin showed higher susceptibility rates against <i>C. glabrata</i>. Rezafungin indicates its potent activity for potential clinical application.
BibTeX
@article{yang2024vitro,
  author = {Simin Yang and Fangru Wan and Min Zhang and Hui‐Ping Lin and Liang Hu and Ziyi Zhou and Dongjiang Wang and Aiping Zhou and Lijun Ni and Jian Guo and Wenjuan Wu},
  title = {{In Vitro Activitiy of Rezafungin in Comparison with Anidulafungin and Caspofungin against Invasive Fungal Isolates (2017 to 2022) in China}},
  journal = {Journal of Fungi},
  year = {2024},
  doi = {10.3390/jof10060397},
}
Figure